Podocyte Expression of Osteopontin and FSP-1/S100A4 in Human Crescentic Glomerulonephritis

BACKGROUND: Osteopontin (OPN) is a cytokine associated with a cell-matrix via integrins. Fibroblast specific protein-1 (FSP-1), known as S100A4, has been implicated in cell migration by non-muscle myosin. We investigated whether the role of OPN and FSP-1/S100A4 expression in their contribution to the podocyte phenotype change to form podocyte bridge and cellular crescent. METHODS: Glomerular expression of OPN and FSP-1/S100A4 in renal biopsies of 16 patients with crescentic glomerulonephritis (CrGN) and 13 normal renal biopsies were studied by immunohistochemistry. RESULTS: The expression of OPN and FSP-1/S100A4 was increased in the podocytes of glomeruli, with and without crescents, in patients with CrGN. Neither OPN nor FSP-1/S100A4 was expressed in glomeruli from the normal controls (p<0.01). A significant positive correlation was found between the expression of OPN in glomerular tufts and cellular crescents, and the expression of OPN and FSP-1/S100A4 in glomerular tufts (p<0.05). CONCLUSIONS: The results suggest that OPN plays a role in early podocyte attachment to Bowman's capsule, and FSP-1/S100A4 potentiate podocyte contribution to cellular crescent formation by inducing cellular migration and growth.

Clinicopathological Significance of S100A4 Expression in Non-small Cell Lung Carcinomas

BACKGROUND: S100A4 has been implicated in invasion and metastasis of various malignant tumors. The aim of this study was to investigate whether or not S100A4 plays an important role in non-small cell lung carcinomas (NSCLCs). METHODS: Sixty-seven patients with NSCLC including 37 with squamous cell carcinomas (SCCs) and 30 with adenocarcinomas (ADs) who had undergone surgical resection were analyzed. S100A4 expression was analyzed by immunohistochemistry using tissue microarray blocks. RESULTS: S100A4 expression was positive in 56 (83.6%) of 67 NSCLC cases. ADs were more frequently S100A4 positive than SCCs (p = 0.017). However, no significant correlation was observed between S100A4 expression and age, gender, pT, pN or tumor, node and metastasis (TNM) stage. Two distant metastatic cases revealed an S100A4 positive reaction. Kaplan-Meier survival curves with the log-rank test showed no correlation with 3-year survival (p = 0.782) or 5-year survival (p = 0.227) in either group of patients according to S100A4 expression. CONCLUSIONS: S100A4 expression was not correlated with age, gender, pT, pN or TNM stage or survival in patients with NSCLCs. Therefore, S100A4 expression may not be useful as a prognostic marker for NSCLCs. However, S100A4 expression showed a higher positivity in ADs than in SCCs.

Significance of S100A2 and S100A4 Expression in the Progression of Prostate Adenocarcinoma

PURPOSE: The aim of this study was to investigate the expression pattern of calcium-binding proteins S100A2 and S100A4. We also sought to determine the prognostic value of these markers for patients with prostate adenocarcinoma. MATERIALS AND METHODS: Immunohistochemical staining was performed to detect S100A2 and S100A4 expression in 26 tissue samples obtained during transurethral resection from patients with benign prostatic hyperplasia (BPH) and in 67 tissue samples obtained during prostate biopsy and radical prostatectomy from patients with prostate carcinoma. The immunoreactivity of these proteins was stratified on a scale of 0 to 3 and was correlated with the pathologic features of prostate adenocarcinoma. RESULTS: High expression of S100A2 was observed in the tissue of patients with BPH, whereas low or no expression was observed in prostate cancer (CaP) cells. The protein level of S100A4 was significantly higher in CaP than in BPH cells. The higher level of S100A4 observed in CaP tissue correlated with increasing tumor grade. CONCLUSIONS: Decreased expression of S100A2 and increased expression of S100A4 may be important in the progression of CaP. This finding could aid in identifying aggressive CaP. The simultaneous analysis of S100A2 and S100A4 expression in prostate tissues may be a useful prognostic marker for CaP.

Significance of S100A2 and S100A4 Expression in the Progression of Prostate Adenocarcinoma

PURPOSE: The aim of this study was to investigate the expression pattern of calcium-binding proteins S100A2 and S100A4. We also sought to determine the prognostic value of these markers for patients with prostate adenocarcinoma. MATERIALS AND METHODS: Immunohistochemical staining was performed to detect S100A2 and S100A4 expression in 26 tissue samples obtained during transurethral resection from patients with benign prostatic hyperplasia (BPH) and in 67 tissue samples obtained during prostate biopsy and radical prostatectomy from patients with prostate carcinoma. The immunoreactivity of these proteins was stratified on a scale of 0 to 3 and was correlated with the pathologic features of prostate adenocarcinoma. RESULTS: High expression of S100A2 was observed in the tissue of patients with BPH, whereas low or no expression was observed in prostate cancer (CaP) cells. The protein level of S100A4 was significantly higher in CaP than in BPH cells. The higher level of S100A4 observed in CaP tissue correlated with increasing tumor grade. CONCLUSIONS: Decreased expression of S100A2 and increased expression of S100A4 may be important in the progression of CaP. This finding could aid in identifying aggressive CaP. The simultaneous analysis of S100A2 and S100A4 expression in prostate tissues may be a useful prognostic marker for CaP.

Significance of S100A4 expression in benign and malignant thyroid tissue / 中华内分泌外科杂志

Objective To investigate the expression of S100A4 protein in benign and malignant thyroid tissues and its clinical significance. Methods Expression of S100A4 protein in thyroid cancers (50 cases), adenoma (45 cases) and adjacent noncancerous tissue (20 cases) was respectively studied by microwave-LSAB immunohistochemical staining. Results The positive rate of S100A4 protein in thyroid cancer and adenoma was 78.0% and 15.6% respectively. No S100A4 protein expression was found in any adjacent noncancerous tissue (P ＜0. 01). No correlation was observed between expression of S100A4 protein and histological grading of thyroid cancer. Expression of S100A4 protein in lymph node metastasis and staging Ⅲ-Ⅳ was both higher than that in negative cases and staging Ⅰ -Ⅱ (P ＜0. 05). The rate of recurrence and death in S100A4 protein positive cases were notably higher than that in negative cases (P ＜ 0. 05). Conclusions S100A4 protein expression can help to distinguish benign and malignant thyroid tissues. It can be used as a molecular marker to predict thyroid metastasis.

Expression of S100A4 protein in hepatocellular carcinoma and its clinical implications / 肿瘤

Objective: To explore the expressions of S100A4 protein in hepatocellular carcinoma (HCC), cirrhotic liver, adjacent non-cancerous liver and normal liver tissues and their clinical implications. Methods: Tissue microarray combined with immunohistochemistry (IHC) was used to evaluate the differential expressions of S100A4 protein in HCC-related tissues, and their clinical implications were statistically analyzed. Results: Immunohistochemical staining showed that the positive staining of S100A4 protein was higher in the specimens of primary HCC (70.2%), liver cirrhosis (54.4%), and adjacent non-cancerous liver tissues (41.7%) compared with that in normal liver tissues (0.0%). Biological statistic analysis revealed that S100A4 protein expression influenced the survival time of HCC patients. The patients with weak expression of S100A4 had longer survival time than those with over-expression of S100A4 protein (P = 0.040). Conclusion: The order of the expression levels of S100A4 protein in HCC-related tissues is: HCC>adjacent non-cancerous liver > cirrhotic liver > normal liver. In HCC patients without hepatic microvascular invasion, positive expression of S100A4 protein significantly decreases their postoperative survival rate.